UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/041,030	12/28/2001	Scott Powers	018781-006810US	2471

20350 7590 09/20/2004

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER	
UNGAR, SUSAN NMN	

ART UNIT	PAPER NUMBER
1642	

DATE MAILED: 09/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/041,030	POWERS ET AL.	
	Examiner	Art Unit	
	Susan Ungar	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on *28 December 2001*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☐ Claim(s) *1-37* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) *1-37* are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

1. Claims 1-37 are pending in the application and are currently under prosecution. It is noted that claim 20 has been withdrawn from consideration at this time because the claim language is indefinite and it is not possible for Examiner to determine the meets and bounds of the claim. Upon amendment of claim 20, Examiner will be happy to join claim 20 to the appropriate group.

2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

3. Claims 1 and 5, as drawn to SEQ ID NO:2 or variants thereof, links inventions 1-6. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 1 and 5. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 1. Claims 1-4, 5-7 are drawn to a method of detecting lung cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:2 or a variant thereof with an antibody classified in Class 435, subclass 7.1.

Group 2. Claims 1-4, 5-7 are drawn to a method of detecting colon cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:2 or a variant thereof with an antibody classified in Class 435, subclass 7.1.

Group 3. Claims 1-4, 5-7 are drawn to a method of detecting ovarian cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:2 or a variant thereof with an antibody classified in Class 435, subclass 7.1.

Group 4. Claims 1-2, 4-7 are drawn to a method of detecting lung cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:2 or a variant thereof with a probe for mRNA that encodes SEQ ID NO:2 classified in Class 435, subclass 7.1.

Group 5. Claims 1-2, 4-7 are drawn to a method of detecting colon cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:2 or a variant thereof with a probe for mRNA that encodes SEQ ID NO:2 classified in Class 435, subclass 7.1.

Group 6. Claims 1-2, 4-7 are drawn to a method of detecting ovarian cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:2 or a variant thereof with a probe for mRNA that encodes SEQ ID NO:2 classified in Class 435, subclass 7.1.

4. Claims 1 and 5, as drawn to SEQ ID NO:4 or variants thereof, links inventions 7-12. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 1 and 5. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise

including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 7. Claims 1-4, 5-7 are drawn to a method of detecting lung cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:4 or a variant thereof with an antibody classified in Class 435, subclass 7.1.

Group 8. Claims 1-4, 5-7 are drawn to a method of detecting colon cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:4 or a variant thereof with an antibody classified in Class 435, subclass 7.1.

Group 9. Claims 1-4, 5-7 are drawn to a method of detecting ovarian cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:4 or a variant thereof with an antibody classified in Class 435, subclass 7.1.

Group 10. Claims 1-2, 4-7 are drawn to a method of detecting lung cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:4 or a variant thereof with a probe for mRNA that encodes SEQ ID NO:4 classified in Class 435, subclass 7.1.

Group 11. Claims 1-2, 4-7 are drawn to a method of detecting colon cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:4 or a variant thereof with a probe for mRNA that encodes SEQ ID NO:4 classified in Class 435, subclass 7.1.

Group 12. Claims 1-2, 4-7 are drawn to a method of detecting ovarian cancer cells comprising detecting the overexpression of a polypeptide, SEQ ID NO:4 or a variant thereof with a probe for mRNA that encodes SEQ ID NO:4 classified in Class 435, subclass 7.1.

5. Claims 8 and 11, as drawn to SEQ ID NO:2 or variants thereof, links inventions 13-15. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 8 and 11. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 13. Claims 8-13 are drawn to a method of detecting lung cancer cells comprising detecting a gene encoding SEQ ID NO:2 or a variant thereof classified in Class 435, subclass 6.

Group 14. Claims 8-13 are drawn to a method of detecting colon cancer cells comprising detecting a gene encoding SEQ ID NO:2 or a variant thereof classified in Class 435, subclass 6.

Group 15. Claims 8-13 are drawn to a method of detecting ovarian cancer cells comprising detecting a gene encoding SEQ ID NO:2 or a variant thereof classified in Class 435, subclass 6.

6. Claims 8 and 11, as drawn to SEQ ID NO:4 or variants thereof, links inventions 15-18. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 8 and 11. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 16. Claims 8-13 are drawn to a method of detecting lung cancer cells comprising detecting a gene encoding SEQ ID NO:4 or a variant thereof classified in Class 435, subclass 6.

Group 17. Claims 8-13 are drawn to a method of detecting colon cancer cells comprising detecting a gene encoding SEQ ID NO:4 or a variant thereof classified in Class 435, subclass 6.

Group 18. Claims 8-13 are drawn to a method of detecting ovarian cancer cells comprising detecting a gene encoding SEQ ID NO:4 or a variant thereof classified in Class 435, subclass 6.

6. Claims 14 and 16, as drawn to SEQ ID NO:2 or variants thereof, links inventions 19-24. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 14 and 16. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 19. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of lung cancer comprising detecting a level of SEQ ID NO:2 polypeptide or a variant thereof and comparing it to the level at an earlier time with an antibody classified in Class 435, subclass 7.1.

Group 20. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of colon cancer comprising detecting a level of SEQ ID NO:2 polypeptide or a variant thereof and comparing it to the level at an earlier time with an antibody classified in Class 435, subclass 7.1.

Group 21. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of ovarian cancer comprising detecting copy number of gene encoding SEQ ID NO:2 or a variant thereof and comparing it to the level at an earlier time classified in Class 435, subclass 6.

Group 22. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of lung cancer comprising detecting copy number of gene encoding SEQ ID NO:2 or a variant thereof and comparing it to the level at an earlier time classified in Class 435, subclass 6.

Group 23. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of colon cancer comprising detecting copy number of gene encoding SEQ ID NO:2 or a variant thereof and comparing it to the level at an earlier time classified in Class 435, subclass 6.

Group 24. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of ovarian cancer comprising detecting copy number of gene encoding SEQ ID NO:2 or a variant thereof and comparing it to the level at an earlier time classified in Class 435, subclass 6.

7. Claims 14 and 16, as drawn to SEQ ID NO:4 or variants thereof, links inventions 25-30. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 14 and 16. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 25. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of lung cancer comprising detecting a level of SEQ ID NO:4 polypeptide or a variant thereof and comparing it to the level at an earlier time with an antibody classified in Class 435, subclass 7.1.

Group 26. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of colon cancer comprising detecting a level of SEQ ID NO:4 polypeptide or a variant thereof and comparing it to the level at an earlier time with an antibody classified in Class 435, subclass 7.1.

Group 27. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of ovarian cancer detecting a level of SEQ ID NO:4 polypeptide or a variant thereof and comparing it to the level at an earlier time with an antibody classified in Class 435, subclass 7.1.

Group 28. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of lung cancer comprising detecting copy number of gene encoding SEQ ID NO:4 or a variant thereof and comparing it to the level at an earlier time classified in Class 435, subclass 6.

Group 29. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of colon cancer comprising detecting copy number of gene encoding SEQ ID NO:4 or a variant thereof and comparing it to the level at an earlier time classified in Class 435, subclass 6.

Group 30. Claims 14-18 are drawn to a method of monitoring the efficacy of a therapeutic treatment of ovarian cancer comprising detecting copy number of gene encoding SEQ ID NO:4 or a variant thereof and comparing it to the level at an earlier time classified in Class 435, subclass 6.

Group 31. Claims 19 and 21 are drawn to a method of identifying a compound that inhibits the activity of SEQ ID NO:4, classified in Class 435, subclass 4.

8. Claims 22 and 24, as drawn to SEQ ID NO:2 or variants thereof, links inventions 32-37. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 22 and 24. Upon the

allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 32. Claims 22-27 are drawn to a method of inhibiting proliferation of a lung cancer cell overexpressing SEQ ID NO:2 comprising contacting said cell with an antibody classified in Class 424, subclass 130.1.

Group 33. Claims 22-27 are drawn to a method of inhibiting proliferation of a colon cancer cell overexpressing SEQ ID NO:2 comprising contacting said cell with an antibody classified in Class 424, subclass 130.1.

Group 34. Claims 22-27 are drawn to a method of inhibiting proliferation of a ovarian cancer cell overexpressing SEQ ID NO:2 comprising contacting said cell with an antibody classified in Class 424, subclass 130.1.

Group 35. Claims 22-26,28 are drawn to a method of inhibiting

proliferation of a lung cancer cell overexpressing SEQ ID NO:2 comprising contacting said cell with an antisense polynucleotide classified in Class 536, subclass 23.1.

Group 36. Claims 22-26,28 are drawn to a method of inhibiting proliferation of a colon cancer cell overexpressing SEQ ID NO:2 comprising contacting said cell with an antisense polynucleotide classified in Class 536, subclass 23.1.

Group 37. Claims 22-26,28 are drawn to a method of inhibiting proliferation of a ovarian cancer cell overexpressing SEQ ID NO:2 comprising contacting said cell with an antisense polynucleotide classified in Class 536, subclass 23.1.

9. Claims 22 and 24, as drawn to SEQ ID NO:4 or variants thereof, links inventions 38-43. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claim(s), claims 22 and 24. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Group 38. Claims 22-27 are drawn to a method of inhibiting proliferation of a lung cancer cell overexpressing SEQ ID NO:4 comprising contacting said cell with an antibody classified in Class 424, subclass 130.1.

Group 39. Claims 22-27 are drawn to a method of inhibiting proliferation of a colon cancer cell overexpressing SEQ ID NO:4 comprising contacting said cell with an antibody classified in Class 424, subclass 130.1.

Group 40. Claims 22-27 are drawn to a method of inhibiting proliferation of a ovarian cancer cell overexpressing SEQ ID NO:4 comprising contacting said cell with an antibody classified in Class 424, subclass 130.1.

Group 41. Claims 22-26,28 are drawn to a method of inhibiting proliferation of a lung cancer cell overexpressing SEQ ID NO:4 comprising contacting said cell with an antisense polynucleotide classified in Class 536, subclass 23.1.

Group 42. Claims 22-26,28 are drawn to a method of inhibiting proliferation of a colon cancer cell overexpressing SEQ ID NO:4 comprising contacting said cell with an antisense polynucleotide classified in Class 536, subclass 23.1.

Group 43. Claims 22-26,28 are drawn to a method of inhibiting proliferation of a ovarian cancer cell overexpressing SEQ ID NO:4 comprising contacting said cell with an antisense polynucleotide classified in Class 536, subclass 23.1.

Group 44. Claims 29-33 are drawn to a polynucleotide comprising encoding a polypeptide, SEQ ID NO:4/3, an expression vector and host cell comprising the expression vector, classified in Class 536, subclass 23.1.

Group 45. Claims 34-36 are drawn to a polypeptide, SEQ ID NO:4, classified in Class 530, subclass 350+.

Group 46. Claim 37 is drawn to an antibody that binds to SEQ ID NO:4, classified in Class 530, subclass 387.1.

10. The inventions are distinct, each from the other because of the following reasons:

Inventions 44-46 as disclosed are biologically and chemically distinct, made by and used in different methods and are therefore distinct inventions.

Inventions 1-43 are materially distinct methods which differ at least in objectives, method steps, reagents and/or dosages and/or schedules used, response variables, and criteria for success.

The inventions of Groups 44 and 4-6, 10-12, 13-15, 16-18, 22-24, 28-30, 31, 35-37, 41-43 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (I) the process for using the product as claimed can be practiced with another materially different product or (ii) the product as claimed can be used in a materially different process of using that product [see *MPEP* § **806.05(h)**]. In the instant case the polynucleotide as claimed can be used in a materially different process such as producing a polypeptide.

The inventions of Groups 45/46 and 1-3, 7-9, 19-21, 25-27, 31, 32-34, 38-40 are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (I) the process for using the

product as claimed can be practiced with another materially different product or (ii) the product as claimed can be used in a materially different process of using that product [see *MPEP* § **806.05(h)**]. In the instant case the polypeptide product and the antibody product as claimed can be used in a materially different process such as their use as antigens for the preparation of antibody and anti-idiotypic antibody, respectively.

11 Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or recognized divergent subject matter, restriction for examination purposes as indicated is proper.

12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

13. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103.

14. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

15. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Ungar, PhD whose telephone number is (571) 272-0837. The examiner can normally be reached on Monday through Friday from 7:30am to 4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew, can be reached at 571-272-0787. The fax phone number for this Art Unit is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Effective, February 7, 1998, the Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1642.

Susan Ungar
Primary Patent Examiner
September 9, 2004